ReviewExpert review of gastroenterology & hepatology2008
Advances in antifibrotic therapy.
Review in Expert review of gastroenterology & hepatology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Transcriptional factor KLF9 in pulmonary fibrosis: from molecular mechanisms to precision intervention-a narrative review.Journal of thoracic disease · 2026Review
- Regression of hepatic fibrosis in gamma-irradiated rats by mycophenolate mofetil: potential role of Egr-1.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- KLF4 Inhibits the Activation of Human Hepatic Stellate Cell In Vitro.Current medical science · 2024Article
- Molecular Docking and Dynamic Simulation Revealed the Potential Inhibitory Activity of Opioid Compounds Targeting the Main Protease of SARS-CoV-2.BioMed research international · 2022Article
- Gas6 Ameliorates Inflammatory Response and Apoptosis in Bleomycin-Induced Acute Lung Injury.Biomedicines · 2021Article
- Albumin inhibits the nuclear translocation of Smad3 via interleukin-1beta signaling in hepatic stellate cells.Scientific reports · 2021Article
- Multiple potential targets of opioids in the treatment of acute respiratory distress syndrome from COVID-19.Journal of cellular and molecular medicine · 2021Review
- Article
- Extracellular Vesicles From Hepatocytes Are Therapeutic for Toxin-Mediated Fibrosis and Gene Expression in the Liver.Frontiers in cell and developmental biology · 2019Article
- PSTPIP2 connects DNA methylation to macrophage polarization in CCL4-induced mouse model of hepatic fibrosis.Oncogene · 2018Article
- Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease.Chronic diseases and translational medicine · 2017Review
- miR‑203 inhibits the expression of collagen‑related genes and the proliferation of hepatic stellate cells through a SMAD3‑dependent mechanism.Molecular medicine reports · 2017Article
- Vatalanib, a tyrosine kinase inhibitor, decreases hepatic fibrosis and sinusoidal capillarization in CCl4-induced fibrotic mice.Molecular medicine reports · 2017Article
- Targeting Hepatic Fibrosis in Autoimmune Hepatitis.Digestive diseases and sciences · 2016Review
- Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis.JCI insight · 2016Article
- Knockdown of Astrocyte Elevated Gene-1 Inhibits Activation of Hepatic Stellate Cells.Digestive diseases and sciences · 2016Article
- Chinese medicine CGA formula ameliorates DMN-induced liver fibrosis in rats via inhibiting MMP2/9, TIMP1/2 and the TGF-β/Smad signaling pathways.Acta pharmacologica Sinica · 2016Article
- Ionone Derivatives from the Mycelium of Phellinus linteus and the Inhibitory Effect on Activated Rat Hepatic Stellate Cells.International journal of molecular sciences · 2016Article
- Inverse Association of Plasma Level of Glutathione Peroxidase with Liver Fibrosis in Chronic Hepatitis B: Potential Role of Iron.Middle East journal of digestive diseases · 2016Article
- Experimental evidence for the therapeutic potential of tempol in the treatment of acute liver injury.Molecular and cellular biochemistry · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Sustained progress in defining the molecular pathophysiology of hepatic fibrosis has led to a comprehensive framework for developing antifibrotic therapies. Indeed, the single greatest limitation in bringing new drugs to the clinical setting is a lack of clarity regarding clinical trial and treatment end points, not a lack of promising agents. A range of treatments, including those developed for other indications, as well as those specifically developed for hepatic fibrosis, are nearing or in clinical trials. Most are focused on attacking features of either hepatic injury and/or activated stellate cells and myofibroblasts, which are the primary sources of extracellular matrix (scar) proteins. Thus, features of injury and stellate cell activation provide a useful template for classifying these emerging agents and point to a new class of therapies for patients with fibrosing liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.